Applied Molecular Transport Inc. (NASDAQ: AMTI) has appointed a new senior vice president. Carolyn Finkle, who has been chosen for the role, will report directly to the co-founder and CEO of AMT, Tahir Mahmood.
Finkle could help advance the marketing of the company’s oral biologics product
According to Dr. Mahmood, the company is excited to add Finkle to its executive team. Her experience in regulations aligns with the company’s goal to create oral products. This move would enable AMT to target different markets in the mucosal immunology space.
Dr. Mahmood believes that Finkle will play a viable role in the company as it prepares to interact with regulators worldwide on its Phase 2 data for AMT-101. Finkle has worked over three decades with biotechnology companies worldwide to facilitate product approval, product development, and regulatory strategy.
Finkle’s work experience
Before her role in AMT, Finkle was the COO of Medicago. She was also the VP of regulatory affairs in Karyophram. Moreover, she has worked at Celsion, PAREXEL, MedImmune, Catalent, and inVentiv Health.
Finkle studied at the University of Ottawa, where she earned a Bachelor of Science degree in Chemistry. She also got her Masters Degree from the University of Toronto. Finkle now lectures in Georgetown University.
Finkle expresses her excitement for working at AMT. She points out that the company made ground-breaking advancements in epithelial biology. Now that the company is working on oral biologics, Finkle is excited to join this new phase and bring therapies to patients.
AMT-101, one of the company’s lead projects, is an oral fusion of AMT’s carrier molecule and IL 10. The company is currently conducting four Phase II studies on the drug’s effect on rheumatoid arthritis and inflammatory bowel disease.
AMT has designed the drug to cross the gastrointestinal epithelial barrier while reducing passage into the blood. This design enables the drug to concentrate in the inflammation site and prevents the side effects of systemic administration.
Applied Molecular Transport is a company that designs and develops oral biologic therapies for metabolic, inflammatory, and autoimmune diseases using its technology platform. The company is currently developing oral therapies that target either the circulation or gastrointestinal system to restrict the drug to the affected site.
